| Dr Joseph Kamel Francis, MD | |
|
3260 Gulf Gate Dr, Sarasota, FL 34231-2404 | |
| (941) 867-1776 | |
| (941) 444-6726 |
| Full Name | Dr Joseph Kamel Francis |
|---|---|
| Gender | Male |
| Speciality | Micrographic Dermatologic Surgery (mds) |
| Experience | 17 Years |
| Location | 3260 Gulf Gate Dr, Sarasota, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386841724 | NPI | - | NPPES |
| 006449100 | Medicaid | FL |
| Entity Name | Florida Clinical Practice Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063463768 PECOS PAC ID: 0345146254 Enrollment ID: O20031211000099 |
News Archive
The National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has commissioned a new study to identify the most effective and efficient surveillance methods for women who have received treatment for primary breast cancer.
Biological Engineers at the University of Bath have developed a test that could help medics quickly diagnose urinary tract infections, using a normal smartphone camera.
Many patients diagnosed with prostate cancer have indolent, slow-growing forms of the disease that are not life-threatening. However, more than 30,000 American men will die from aggressive prostate cancer this year alone. This sharp contrast between low-risk and aggressive disease presents a challenge for many researchers and physicians as they diagnose patients and also determine the prognosis of the men with the most aggressive forms of prostate cancer.
Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.
The Wellcome Trust Case Control Consortium, the largest ever study of the genetics behind common diseases such as diabetes, rheumatoid arthritis and coronary heart disease, publishes its results in the journals Nature and Nature Genetics.
› Verified 9 days ago
| Entity Name | Skin Trust Mohs And Dermatology, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154907608 PECOS PAC ID: 4789079286 Enrollment ID: O20220321000631 |
News Archive
The National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has commissioned a new study to identify the most effective and efficient surveillance methods for women who have received treatment for primary breast cancer.
Biological Engineers at the University of Bath have developed a test that could help medics quickly diagnose urinary tract infections, using a normal smartphone camera.
Many patients diagnosed with prostate cancer have indolent, slow-growing forms of the disease that are not life-threatening. However, more than 30,000 American men will die from aggressive prostate cancer this year alone. This sharp contrast between low-risk and aggressive disease presents a challenge for many researchers and physicians as they diagnose patients and also determine the prognosis of the men with the most aggressive forms of prostate cancer.
Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.
The Wellcome Trust Case Control Consortium, the largest ever study of the genetics behind common diseases such as diabetes, rheumatoid arthritis and coronary heart disease, publishes its results in the journals Nature and Nature Genetics.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Kamel Francis, MD 3260 Gulf Gate Dr, Sarasota, FL 34231-2404 Ph: (941) 867-1776 | Dr Joseph Kamel Francis, MD 3260 Gulf Gate Dr, Sarasota, FL 34231-2404 Ph: (941) 867-1776 |
News Archive
The National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has commissioned a new study to identify the most effective and efficient surveillance methods for women who have received treatment for primary breast cancer.
Biological Engineers at the University of Bath have developed a test that could help medics quickly diagnose urinary tract infections, using a normal smartphone camera.
Many patients diagnosed with prostate cancer have indolent, slow-growing forms of the disease that are not life-threatening. However, more than 30,000 American men will die from aggressive prostate cancer this year alone. This sharp contrast between low-risk and aggressive disease presents a challenge for many researchers and physicians as they diagnose patients and also determine the prognosis of the men with the most aggressive forms of prostate cancer.
Watson Pharmaceuticals, Inc., a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.- Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 174 mg and 348 mg strength bupropion hydrobromide tablets prior to the expiration of patents owned by Biovail. Watson's 174 mg and 348 mg strength bupropion hydrobromide tablet products are generic versions of Biovail's Aplenzin™ ER, which is indicated for major depressive disorder.
The Wellcome Trust Case Control Consortium, the largest ever study of the genetics behind common diseases such as diabetes, rheumatoid arthritis and coronary heart disease, publishes its results in the journals Nature and Nature Genetics.
› Verified 9 days ago
Dr. Sena J Lee, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2426 S Tamiami Trl, Sarasota, FL 34239 Phone: 941-955-0360 Fax: 941-955-9806 | |
Steven Mark Burnett, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1545 Mound St, Sarasota, FL 34236 Phone: 941-957-3376 Fax: 941-951-1966 | |
Nicole Patzelt, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 12609 Promenade Estates Blvd, Sarasota, FL 34238 Phone: 201-956-7727 | |
William Elstein, MD Dermatology Medicare: May Accept Medicare Assignments Practice Location: 3920 Bee Ridge Rd, Bldg H Ste K, Sarasota, FL 34233 Phone: 941-923-5455 Fax: 941-925-3257 | |
J Morgan Odonoghue, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1952 Field Rd, Sarasota, FL 34231 Phone: 941-926-7546 Fax: 941-926-2777 | |
Dr. Erin M. Long, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3333 Cattlemen Rd, Suite 106, Sarasota, FL 34232 Phone: 941-379-1799 Fax: 941-379-1899 | |
Joseph J Yohn, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3333 Cattlemen Rd Ste 106, Sarasota, FL 34232 Phone: 941-379-1799 Fax: 941-379-1899 |